Top Injectable Manufacturer in Mongolia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 9 hours ago
- 12 min read
Last Updated: August 29, 2026
TL;DR: Mongolia has a genuine fast-track registration route, and an Indian manufacturer cannot use it. Under the last published version of the registration procedure, the accelerated pathway is reserved for products manufactured in, and approved by, a named list of thirteen “stringent regulatory authorities” built on ICH membership — and India's CDSCO is not among them. What is open is the ordinary route, which asks for registration in the country of manufacture plus three years on that market plus registrations in five further countries, a WHO-format CPP, a GMP certificate whose origin the text does not restrict, in-country laboratory testing at your cost, and a contract with a licensed Mongolian supply organisation, because a foreign manufacturer cannot hold the authorisation itself. Two things make the timing interesting: nearly half of Mongolian health spending is now out-of-pocket, which favours quality-assured low-cost injectables, and UNDP signed a three-year essential-medicines procurement project with the regulator in April 2026. This guide sets out what is verified, what was repealed, and what you must obtain from the regulator before you budget.
Key Takeaways
Mongolia's accelerated registration route is closed to an Indian file. Clause 3.9 of the procedure adopted by Minister of Health Order A/295 of 21 June 2019 named thirteen stringent regulatory authorities — the US FDA, the EMA and the European Commission, EU member state authorities, Japan's MHLW, Swissmedic, Health Canada, ANVISA, Korea's MFDS, Singapore's HSA, China's NMPA, Taiwan's TFDA and Australia's TGA. CDSCO is absent. Important caveat, and we would rather give it to you than have you find it later: that annex was repealed by Order A/206 of 26 May 2025, whose text we could not obtain, so treat the list as the last published version and ask MMRA for the current one.
The ordinary route is the one that is actually open, and its barrier is documentary rather than scientific. Under the 2019 procedure an imported medicine had to be registered in its country of manufacture and either marketed there for at least three years and registered in at least five further countries, or registered in a country having a recognised stringent authority. Budget for the paperwork, not for a science argument.
A foreign manufacturer cannot hold a Mongolian marketing authorisation directly. The registrant must be a licensed Mongolian supply organisation, an international supply organisation with a quality management system, a representative office entitled to represent the manufacturer, or a national manufacturer — and the dossier must contain the registration contract with that party. Changing the holder is treated as a minor change, so the partner decision is reversible more cheaply than most.
Two market realities favour a WHO-GMP Indian supplier right now. Out-of-pocket spending rose from 39 percent of current health expenditure in 2022 to 48.8 percent in 2023 while spending per capita fell from US$448 to US$360, which is an affordability problem that quality-assured generics answer. And in April 2026 UNDP signed a three-year Procurement of Essential Medicines project with the regulator, adding a channel that runs on international procurement and quality-assurance standards.
Introduction: Why Mongolia Demands a Premium Injectable Manufacturer in Mongolia
Mongolia is a market of roughly 3.52 million people — the World Bank puts the 2024 population at 3,524,788 and gross national income per capita at US$5,380 — spread across the sixth-largest country in Asia with no coastline and exactly two neighbours. That combination does most of the work in explaining why supplying it is unlike supplying anywhere else. The health economics are moving quickly and not in a comfortable direction: current health expenditure per capita fell from US$448.24 in 2022 to US$359.61 in 2023, spending dropped from 8.85 percent of GDP to 6.07 percent, and the share paid directly by patients out of pocket rose from 38.95 percent to 48.80 percent. Almost half of what Mongolia spends on health is now paid at the point of care by the person receiving it. The disease burden that money has to meet is heavy. WHO's 2024 estimate puts tuberculosis incidence at 446 per 100,000 — and that figure carries a confidence interval of 240 to 713, which is wide enough that it should never be quoted without it. GLOBOCAN 2024 records 7,240 new cancer cases and 5,015 cancer deaths, a mortality-to-incidence ratio near 69 percent that points to late presentation, with liver cancer alone accounting for 2,230 cases. One methodological note, because it matters: IARC records no country-specific incidence source for Mongolia, so those incidence figures are modelled from national mortality data rather than observed in a registry.
The regulatory picture is where most supplier content goes wrong, and it goes wrong in a predictable direction — by treating a fast pathway as an available one. Article 22.5 of the Law on Medicines and Medical Devices provides that medicines registered by an internationally recognised drug control institution shall be registered on an accelerated basis, and delegates the definition of that institution to ministerial order. The order then names a closed list. Under the procedure adopted by Order A/295 of 21 June 2019, clause 3.9 enumerated thirteen authorities, all of them anchored to ICH membership, and India's CDSCO was not one of them. Nor is WHO prequalification a general shortcut — clause 3.5 makes it an additional requirement for vaccines and tuberculosis medicines in WHO-PQ categories rather than a way around anything. This is now the fourth market in our recent country series where a regime that reads as liberal turns out to be shut to an Indian file, and the honest conclusion is the same each time: a liberal regime is not the same thing as an open one, and you should check whose name is on the list before you plan around the list.
What Sets a World-Class Injectable Manufacturer in Mongolia Apart
The ordinary registration route is open, and the discipline it demands is documentary. Under the 2019 procedure the dossier for an imported medicine ran to twenty-two enumerated items filed partly through the LICEMED system and partly on paper, in Mongolian, English or Russian, with certified translation for anything else. It is not an ICH CTD structure — the procedure prescribes its own list, and a team that arrives with modules and no mapping will spend weeks reformatting. Among the items: an original application signed and sealed by an authorised officer of the manufacturer; the registration contract with the Mongolian supply organisation; a manufacturer-certified copy of the GMP certificate; a certificate of a pharmaceutical product in WHO format, original or officially certified, with the summary of product characteristics attached; proof of registration in a stringent-authority country or in at least five other countries; a plant profile translated into Mongolian; finished-product certificates of analysis and analytical methods; stability data supporting the claimed shelf life; batch manufacturing instructions and a process flow with in-process controls; bioequivalence data where the dosage form requires it; colour artwork of primary and secondary packaging with physical samples; a package insert in Mongolian approved by the pharmacology sub-council; a post-marketing surveillance work plan; and — a genuinely unusual one — a price comparison study against domestic wholesale and retail prices.
Three features of that regime deserve to be flagged before anyone budgets. First, in-country laboratory testing by an accredited laboratory under contract to the authority was mandatory, and expressly waived only for fast-track filings — which an Indian applicant cannot use. The cost of that testing, and the supply of reference standards and reagents, sat with the applicant. Mongolia inaugurated a new National Reference Laboratory for Medicines and Medical Devices on 16 June 2026 with WHO support and Pandemic Fund financing, so that capacity is being strengthened as we write. Second, the 2019 procedure contained a market-saturation rule with real commercial bite: a medicine would not be registered where the same active ingredient, strength and dosage form was already registered from more than ten manufacturers, again except on the fast-track. Check the register for your molecule before you spend anything. Third, decisions were taken by the Human Medicines Council sitting in session rather than by a desk reviewer, which changes how you prepare and when you can expect an outcome. We must be straight with you about the status of all of this: these clauses come from Annex 1 of Order A/295, which the state legal gazette records as repealed by Order A/206 of 26 May 2025, and we were unable to obtain the 2025 text. Any supplier quoting you today's Mongolian requirements with confidence should be asked which instrument they are reading.
Quality Systems Behind Every Injectable Supplied to Mongolia
On GMP, the accurate statement is narrower than the one you will usually be given, and the difference matters. A GMP certificate is a mandatory dossier item, submitted as a manufacturer-certified copy, and a WHO-format CPP is separately mandatory. The general registration criterion is simply that the manufacturer meets the requirements of Good Manufacturing Practice. What the text does not do is restrict whose GMP certificate counts. There is no clause naming WHO-GMP, no clause naming CDSCO or an Indian State Licensing Authority, and equally no clause excluding them. That is a permissive silence rather than an express acceptance, and it is a meaningfully better position than the one Uruguay's Decreto 18/020 creates, where the accepted issuers are enumerated and India is not among them. We would not tell you Mongolia formally accepts an Indian WHO-GMP certificate, because no instrument we read says so. We would tell you that nothing we read excludes it, and that you should get MMRA's current practice in writing.
The landlocked question deserves an honest answer rather than a confident one. Mongolia borders China and Russia and nothing else, and a great deal of what circulates about routing, transit times and cold-chain lanes into Ulaanbaatar comes from freight-forwarder marketing rather than from any published rule. We are not going to give you a transit time we cannot source. What we can give you is a regulatory constraint that is verified and that we have not seen discussed anywhere: under the 2010 text of the Law on Medicines and Medical Devices, the import permit specifies the quantities, the manufacturer names, the period for crossing the border and the specific border port. The crossing point is fixed on the permit. For a consignment held at 2–8°C facing a delay at that port, you cannot simply divert to another one — and the same law penalises the import of expired product, which makes shelf-life-on-arrival a regulatory exposure and not merely a commercial one. Plan the remaining-shelf-life margin, the permit's crossing window and the excursion protocol together, because in Mongolia they are the same problem. Note also that these import-permit provisions are from the 2010 revised law; a revised Law took effect on 1 October 2024 and we have not read it, so confirm they stand.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Mongolia for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. What we bring to a Mongolian file is not a promise to shorten a timeline we do not control. It is the documentary depth the ordinary route actually asks for: a manufacturing history long enough to satisfy the marketed-for-three-years test, a registration footprint wide enough to satisfy the five-countries test, and the analytical package — HPLC and GC assay and impurity methods, LAL endotoxin testing, Karl Fischer moisture determination, sterility and container-closure integrity data — assembled so that a reviewer can follow it without a query round. Stability is run under ICH Q1A(R2) and Q1B protocols, which matters more than usual here because the shelf life you claim has to survive a long inland leg before it reaches a patient.
We also build the file the way Mongolia asks for it rather than the way we already have it. Our master dossiers are maintained in CTD and ACTD structure for the markets that want them, and we do not pretend that structure is what Mongolia prescribes — the procedure sets out its own enumerated list, and our regulatory team maps our source documents onto that list item by item, including the ones that have no CTD equivalent at all. The price comparison study against domestic wholesale and retail prices is one of those. So is the post-marketing surveillance work plan, and so is the pharmacovigilance commitment that follows registration: safety reports every six months for the first three years, annually for the next two, and again at renewal. We prepare the plant profile for translation into Mongolian, we supply reference standards and reagents for the mandatory in-country laboratory testing at our own cost rather than leaving your partner to source them, and we hold the artwork and sample sets ready so the packaging review does not become the thing that stalls the file.
Finally, we work through your structure rather than around it. Because a foreign manufacturer cannot hold the Mongolian authorisation, everything depends on the registration contract with a licensed Mongolian supply organisation or a representative office, and we draft to support that relationship rather than to constrain it — helped by the fact that a change of registration holder is treated as a minor change, so the arrangement is not a trap. Where the route is a procurement one rather than a commercial one, we can support that too: recent amendments to the medicines law and to the state procurement law created a legal basis for direct procurement from foreign manufacturers, the Ministry of Health contracted directly with a Korean manufacturer in November 2024, and in April 2026 UNDP and the regulator signed a three-year Procurement of Essential Medicines project applying international procurement and quality-assurance standards, with an initial focus on haemophilia. We will not tell you what that project's eligibility criteria are, because the announcement did not state them. We will tell you that a WHO-GMP dossier is the document such channels normally start from, and that India's own regulator holds WHO maturity level 3 while Mongolia's is not yet on WHO's ML3/ML4 list and is preparing to be benchmarked. India's mission in Ulaanbaatar was still pursuing recognition of Indian Pharmacopoeia standards as of the Ministry of External Affairs brief dated July 2026 — pursuing, not concluded. On the numbers, India reported US$8,263,672 of HS Chapter 30 exports to Mongolia in 2024 against US$7,582,642 in 2023, while Mongolia's own 2023 import figure from India was US$10,496,491, notably higher than India's export figure for the same flow.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Can an Indian manufacturer use Mongolia's fast-track registration route?
On the last published text, no. Clause 3.9 of the procedure adopted by Minister of Health Order A/295 of 21 June 2019 named thirteen stringent regulatory authorities built around ICH membership, and neither India nor CDSCO appeared among them. The clause also required manufacture in a stringent-authority country as well as approval by one, excluded biologicals, vaccines, diagnostics and bioactive products, and required the product to sit on the WHO or Mongolian essential medicines list. Two honest caveats. First, that annex was repealed by Order A/206 of 26 May 2025 and we could not obtain the replacement, so ask MMRA for the current list before relying on this. Second, whether an Indian-made product that holds a US FDA or EMA approval qualifies is genuinely ambiguous on the wording, because the clause appears to require both manufacture and approval in a listed country. That is a question for Mongolian counsel, not for a blog.
Does Mongolia accept a WHO-GMP certificate from an Indian plant?
Nothing we read excludes it, and nothing we read expressly accepts it. A GMP certificate is mandatory, submitted as a manufacturer-certified copy, and a WHO-format CPP is separately mandatory. The registration criterion is stated simply as the manufacturer meeting GMP requirements, without naming an acceptable issuer. So the position is a permissive silence rather than a recognition. We flag it that way deliberately: a supplier who tells you Mongolia formally recognises Indian WHO-GMP is asserting more than the published text supports. Whether MMRA conducts an on-site inspection of an Indian plant, at what trigger and at what cost, we could not establish — though the 2019 fee schedule did carry a GMP expert's fee line item, which suggests some form of GMP assessment is charged for.
Do we need a Mongolian partner, or can we register in our own name?
You need a Mongolian party. Under the 2019 procedure the registrant had to be one of four things: a Mongolian medicines supply organisation holding a special licence, an international supply organisation with a quality management system, a representative office legally entitled to represent the manufacturer in Mongolia, or a national manufacturer. The dossier had to contain the registration contract with that party. A foreign manufacturer could not hold the authorisation itself. The mitigating detail is that a change of the registration-holding organisation is classed as a minor change and need only be registered with the regulator, so switching partners is administratively cheap by the standards of this region. Note that the 2024 revised Law introduced a new licensing framework which we have not read.
How long does registration take and what does it cost?
We are not going to give you a number we cannot source, and you should be wary of anyone who does. What is verified is that the fast-track route carried a decision period of up to three months; the total duration of the ordinary route was not something we could extract, and it is the ordinary route that applies to an Indian file. On fees, the 2019 procedure set a schedule payable in US dollars at the Bank of Mongolia rate and non-refundable, with separate line items for fast-track and ordinary registration of an imported medicine — but the current amounts sit in the 2025 procedure, which we could not obtain. You will also see a widely repeated claim that Mongolia runs a thirty-day and a sixty-day PIC/S track. We found no Mongolian instrument supporting it, it appears only in consultancy marketing, and it contradicts the three-month period the procedure actually states. Registration validity was five years under the 2019 text.
What should we plan for on logistics, being landlocked between China and Russia?
Plan around one verified constraint and treat everything else as a question for your freight partner. The constraint: under the 2010 text of the Law on Medicines and Medical Devices, the import permit names the specific border port and the period within which the crossing must happen. You do not have routing flexibility once the permit is issued, so a cold-chain consignment delayed at that crossing cannot simply be diverted. Combine that with the fact that importing expired product is penalised, and remaining shelf life on arrival becomes a compliance question rather than a commercial preference. What we will not tell you is transit times, corridor comparisons, customs clearance durations or whether Mongolia has formal Good Distribution Practice rules — we could not source any of it from an authoritative Mongolian source, and the freight-forwarder pages that dominate search results are not one. The Ministry of External Affairs itself attributes the modest scale of India–Mongolia trade to geographical transportation challenges, which is a fair summary of the problem.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments